SCM
AMAM

Suvretta Capital Management’s Ambrx Biopharma Inc AMAM Stock Holding History

Suvretta Capital Management’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,491,832
Closed -$1.61M – 110
2022
Q3 		$1.61M Hold
1,491,832
– – 0.07% 67
2022
Q2 		$3.95M Hold
1,491,832
– – 0.15% 69
2022
Q1 		$6.15M Buy
1,491,832
+434,097
+41% +$2.22M 0.19% 60
2021
Q4 		$9.55M Buy
+1,057,735
New +$11.8M 0.18% 63
2021
Q3 		– Sell
-1,169,529
Closed -$22.9M – 136
2021
Q2 		$22.9M Buy
+1,169,529
New +$19.9M 0.34% 59

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Suvretta Capital Management's AMAM Position: Q4 2022 in Review

Suvretta Capital Management sold out of Ambrx Biopharma Inc (AMAM) in Q4 2022, closing a stake of 1,491,832 shares — an estimated $1.61M sold.

Suvretta Capital Management first reported a position in AMAM in Q2 2021 and held it in 5 quarters. The position peaked at $22.9M in Q2 2021. 18 funds tracked by Wall St. Rank hold AMAM as of Q4 2022.

  • Suvretta Capital Management reported no remaining Ambrx Biopharma Inc position as of Q4 2022 after selling out during the quarter.
  • Suvretta Capital Management sold 1,491,832 Ambrx Biopharma Inc shares in Q4 2022, an estimated $1.61M.
  • Suvretta Capital Management first reported a position in Ambrx Biopharma Inc in Q2 2021 and held it in 5 quarters.
  • Suvretta Capital Management's Ambrx Biopharma Inc position peaked at $22.9M in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q4 2022.

Based on Suvretta Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.